Generic placeholder image

Current Alzheimer Research

Editor-in-Chief

ISSN (Print): 1567-2050
ISSN (Online): 1875-5828

Review Article

The Relationship of Anxiety with Alzheimer’s Disease: A Narrative Review

Author(s): Palak Patel and Arjun V. Masurkar*

Volume 18 , Issue 5 , 2021

Published on: 23 August, 2021

Page: [359 - 371] Pages: 13

DOI: 10.2174/1567205018666210823095603

Price: $65

Abstract

Background: There is an increased effort to better understand neuropsychiatric symptoms of Alzheimer’s Disease (AD) as an important feature of symptomatic burden as well as potential modifiable factors of the disease process. Anxiety is one of the most common neuropsychiatric symptoms in Alzheimer’s Disease (AD). A growing body of work has emerged that addresses the epidemiology and biological correlations of anxiety in AD.

Methods: Here, we review human studies in research and clinical cohorts that examined anxiety in AD. We focused on work related to prevalence across AD stages, correlation with established biomarkers, relationship with AD neuropathology and genetic risk factors, and impact on progression.

Results: Anxiety is prominent in the early stages and increases across the spectrum of functional stages. Biomarker relationships are strongest at the level of FDG-PET and amyloid measured via PET or cerebrospinal fluid analysis. Neuropathologically, anxiety emerges with early Braak stage tau pathology. The presence of the apolipoprotein E e4 allele is associated with increased anxiety at all stages, most notably at mild cognitive impairment. Anxiety portended a faster progression at all predementia stages.

Conclusion: This body of work suggests a close biological relationship between anxiety and AD that begins in early stages and influences functional decline. As such, we discuss future work that would improve our understanding of this relationship and test the validity of anxiolytic treatment as disease modifying therapy for AD.

Keywords: Anxiety, Alzheimer's disease, neuropsychiatric, early stage, preclinical, prodromal.

[1]
Alzheimer’s Association Report. 2020 Alzheimer’s disease facts and figures. Alzheimers Dement 2020; 16(3): 391-460.
[http://dx.doi.org/10.1002/alz.12068] [PMID: 32157811]
[2]
Sperling RA, Aisen PS, Beckett LA, et al. Toward defining the preclinical stages of Alzheimer’s disease: Recommendations from the National Institute on Aging-Alzheimer’s Association workgroups on diagnostic guidelines for Alzheimer’s disease. Alzheimers Dement 2011; 7(3): 280-92.
[http://dx.doi.org/10.1016/j.jalz.2011.03.003] [PMID: 21514248]
[3]
Burhanullah MH, Tschanz JT, Peters ME. Neuropsychiatric symptoms as risk factors for cognitive decline in clinically normal older adults: The cache county study. Am J Geriatr Psychiatry 2020; 28(1): 64-71.
[http://dx.doi.org/10.1016/j.jagp.2019.03.023] [PMID: 31186157]
[4]
Geda YE, Roberts RO, Knopman DS, et al. Prevalence of neuropsychiatric symptoms in mild cognitive impairment and normal cognitive aging: Population-based study. Arch Gen Psychiatry 2008; 65(10): 1193-8.
[http://dx.doi.org/10.1001/archpsyc.65.10.1193] [PMID: 18838636 ]
[5]
Khundakar AA, Thomas AJ. Neuropathology of depression in Alzheimer’s disease: Current knowledge and the potential for new treatments. J Alzheimers Dis 2015; 44(1): 27-41.
[http://dx.doi.org/10.3233/JAD-148003] [PMID: 25208623]
[6]
Mortby ME, Burns R, Eramudugolla R, Ismail Z, Anstey KJ. Neuropsychiatric symptoms and cognitive impairment: Understanding the importance of co-morbid symptoms. J Alzheimers Dis 2017; 59(1): 141-53.
[http://dx.doi.org/10.3233/JAD-170050] [PMID: 28598846]
[7]
Wise EA, Rosenberg PB, Lyketsos CG, Leoutsakos JM. Time course of neuropsychiatric symptoms and cognitive diagnosis in National Alzheimer’s Coordinating Centers volunteers. Alzheimers Dement (Amst) 2019; 11: 333-9.
[http://dx.doi.org/10.1016/j.dadm.2019.02.006] [PMID: 31024987]
[8]
Zhang M, Wang H, Li T, Yu X. Prevalence of neuropsychiatric symptoms across the declining memory continuum: An observational study in a memory clinic setting. Dement Geriatr Cogn Disord Extra 2012; 2: 200-8.
[http://dx.doi.org/10.1159/000338410] [PMID: 22719746]
[9]
Jack CR Jr, Bennett DA, Blennow K, et al. Nia-aa research framework: Toward a biological definition of Alzheimer’s disease. Alzheimers Dement 2018; 14(4): 535-62.
[http://dx.doi.org/10.1016/j.jalz.2018.02.018] [PMID: 29653606]
[10]
Reisberg B, Ferris SH, de Leon MJ, Crook T. The global deterioration scale for assessment of primary degenerative dementia. Am J Psychiatry 1982; 139(9): 1136-9.
[http://dx.doi.org/10.1176/ajp.139.9.1136] [PMID: 7114305]
[11]
Reisberg B, Franssen E, Sclan S, Kluger A, Ferris SH. Stage specific incidence of potentially remediable behavioral symptoms in aging and Alzheimer disease: a study of 120 patients using the BEHAVE-AD. Bull Clin Neurosci 1989; 54: 95-112.
[PMID: 2690101]
[12]
Reisberg B, Torossian C, Shulman MB, et al. Two year outcomes, cognitive and behavioral markers of decline in healthy, cognitively normal older persons with global deterioration scale stage 2 (subjective cognitive decline with impairment). J Alzheimers Dis 2019; 67(2): 685-705.
[http://dx.doi.org/10.3233/JAD-180341] [PMID: 30689585]
[13]
Sheikh F, Ismail Z, Mortby ME, et al. Prevalence of mild behavioral impairment in mild cognitive impairment and subjective cognitive decline, and its association with caregiver burden. Int Psychogeriatr 2018; 30(2): 233-44.
[http://dx.doi.org/10.1017/S104161021700151X] [PMID: 28879833]
[14]
Slot RER, Verfaillie SCJ, Overbeek JM, et al. Subjective cognitive impairment cohort (science): Study design and first results. Alzheimers Res Ther 2018; 10(1): 76.
[http://dx.doi.org/10.1186/s13195-018-0390-y] [PMID: 30081935]
[15]
Feldman H, Scheltens P, Scarpini E. Behavioral symptoms in mild cognitive impairment. Neurology 2004; 62(7): 1199-201.
[http://dx.doi.org/10.1212/01.WNL.0000118301.92105.EE] [PMID: 15079026]
[16]
Forsell Y, Palmer K, Fratiglioni L. Psychiatric symptoms/syndromes in elderly persons with mild cognitive impairment. Data from a cross-sectional study. Acta Neurol Scand Suppl 2003; 179: 25-8.
[http://dx.doi.org/10.1034/j.1600-0404.107.s179.4.x] [PMID: 12603247]
[17]
Geda YE, Smith GE, Knopman DS, et al. De novo genesis of neuropsychiatric symptoms in mild cognitive impairment (MCI). Int Psychogeriatr 2004; 16(1): 51-60.
[http://dx.doi.org/10.1017/S1041610204000067] [PMID: 15190996]
[18]
Lopez OL, Becker JT, Sweet RA. Non-cognitive symptoms in mild cognitive impairment subjects. Neurocase 2005; 11(1): 65-71.
[http://dx.doi.org/10.1080/13554790490896893] [PMID: 15804926]
[19]
Lyketsos CG, Lopez O, Jones B, Fitzpatrick AL, Breitner J, DeKosky S. Prevalence of neuropsychiatric symptoms in dementia and mild cognitive impairment: Results from the cardiovascular health study. JAMA 2002; 288(12): 1475-83.
[http://dx.doi.org/10.1001/jama.288.12.1475] [PMID: 12243634]
[20]
Rosenberg PB, Mielke MM, Appleby B, Oh E, Leoutsakos JM, Lyketsos CG. Neuropsychiatric symptoms in MCI subtypes: The importance of executive dysfunction. Int J Geriatr Psychiatry 2011; 26(4): 364-72.
[http://dx.doi.org/10.1002/gps.2535] [PMID: 20845402]
[21]
Siafarikas N, Selbaek G, Fladby T, Šaltytė Benth J, Auning E, Aarsland D. Frequency and subgroups of neuropsychiatric symptoms in mild cognitive impairment and different stages of dementia in Alzheimer’s disease. Int Psychogeriatr 2018; 30(1): 103-13.
[http://dx.doi.org/10.1017/S1041610217001879] [PMID: 28927477]
[22]
Hwang TJ, Masterman DL, Ortiz F, Fairbanks LA, Cummings JL. Mild cognitive impairment is associated with characteristic neuropsychiatric symptoms. Alzheimer Dis Assoc Disord 2004; 18(1): 17-21.
[http://dx.doi.org/10.1097/00002093-200401000-00004] [PMID: 15195459]
[23]
Robert PH, Berr C, Volteau M, et al. Neuropsychological performance in mild cognitive impairment with and without apathy. Dement Geriatr Cogn Disord 2006; 21(3): 192-7.
[http://dx.doi.org/10.1159/000090766] [PMID: 16424666]
[24]
Aalten P, Verhey FR, Boziki M, et al. Neuropsychiatric syndromes in dementia. Results from the European Alzheimer Disease Consortium: Part I. Dement Geriatr Cogn Disord 2007; 24(6): 457-63.
[http://dx.doi.org/10.1159/000110738] [PMID: 17986816]
[25]
Fernández M, Gobartt AL, Balañá M, Group CS. Behavioural symptoms in patients with Alzheimer’s disease and their association with cognitive impairment. BMC Neurol 2010; 10: 87.
[http://dx.doi.org/10.1186/1471-2377-10-87] [PMID: 20920205]
[26]
Fernández Martínez M, Castro Flores J, Pérez de las Heras S, Mandaluniz Lekumberri A, Gordejuela Menocal M, Zarranz Imirizaldu JJ. Prevalence of neuropsychiatric symptoms in elderly patients with dementia in Mungialde County (Basque Country, Spain). Dement Geriatr Cogn Disord 2008; 25(2): 103-8.
[http://dx.doi.org/10.1159/000112215] [PMID: 18063866]
[27]
Karttunen K, Karppi P, Hiltunen A, et al. Neuropsychiatric symptoms and quality of life in patients with very mild and mild Alzheimer’s disease. Int J Geriatr Psychiatry 2011; 26(5): 473-82.
[http://dx.doi.org/10.1002/gps.2550] [PMID: 21445998]
[28]
Lyketsos CG, Sheppard JM, Steinberg M, et al. Neuropsychiatric disturbance in Alzheimer’s disease clusters into three groups: The Cache County study. Int J Geriatr Psychiatry 2001; 16(11): 1043-53.
[http://dx.doi.org/10.1002/gps.448] [PMID: 11746650]
[29]
Tatsch MF, Bottino CM, Azevedo D, et al. Neuropsychiatric symptoms in Alzheimer disease and cognitively impaired, nondemented elderly from a community-based sample in Brazil: Prevalence and relationship with dementia severity. Am J Geriatr Psychiatry 2006; 14(5): 438-45.
[http://dx.doi.org/10.1097/01.JGP.0000218218.47279.db] [PMID: 16670248]
[30]
Teri L, Ferretti LE, Gibbons LE, et al. Anxiety of Alzheimer’s disease: Prevalence, and comorbidity. J Gerontol A Biol Sci Med Sci 1999; 54(7): M348-52.
[http://dx.doi.org/10.1093/gerona/54.7.M348] [PMID: 10462166]
[31]
Treiber KA, Lyketsos CG, Corcoran C, et al. Vascular factors and risk for neuropsychiatric symptoms in Alzheimer’s disease: The Cache County Study. Int Psychogeriatr 2008; 20(3): 538-53.
[http://dx.doi.org/10.1017/S1041610208006704] [PMID: 18289451]
[32]
van Vliet D, de Vugt ME, Aalten P, et al. Prevalence of neuropsychiatric symptoms in young-onset compared to late-onset alzheimer’s disease - part 1: Findings of the two-year longitudinal NeedYD-study. Dement Geriatr Cogn Disord 2012; 34(5-6): 319-27.
[http://dx.doi.org/10.1159/000342824] [PMID: 23208452]
[33]
Cheng ST, Kwok T, Lam LC. Neuropsychiatric symptom clusters of Alzheimer’s disease in Hong Kong Chinese: Prevalence and confirmatory factor analysis of the Neuropsychiatric Inventory. Int Psychogeriatr 2012; 24(9): 1465-73.
[http://dx.doi.org/10.1017/S1041610212000609] [PMID: 22717370]
[34]
Chiu MJ, Chen TF, Yip PK, Hua MS, Tang LY. Behavioral and psychologic symptoms in different types of dementia. J Formos Med Assoc 2006; 105(7): 556-62.
[http://dx.doi.org/10.1016/S0929-6646(09)60150-9] [PMID: 16877235]
[35]
Chow TW, Liu CK, Fuh JL, et al. Neuropsychiatric symptoms of Alzheimer’s disease differ in Chinese and American patients. Int J Geriatr Psychiatry 2002; 17(1): 22-8.
[http://dx.doi.org/10.1002/gps.509] [PMID: 11802226]
[36]
D’Onofrio G, Sancarlo D, Panza F, et al. Neuropsychiatric symptoms and functional status in Alzheimer’s disease and vascular dementia patients. Curr Alzheimer Res 2012; 9(6): 759-71.
[http://dx.doi.org/10.2174/156720512801322582] [PMID: 22715983]
[37]
Fuh JL, Wang SJ, Cummings JL. Neuropsychiatric profiles in patients with Alzheimer’s disease and vascular dementia. J Neurol Neurosurg Psychiatry 2005; 76(10): 1337-41.
[http://dx.doi.org/10.1136/jnnp.2004.056408] [PMID: 16170072]
[38]
Hart DJ, Craig D, Compton SA, et al. A retrospective study of the behavioural and psychological symptoms of mid and late phase Alzheimer’s disease. Int J Geriatr Psychiatry 2003; 18(11): 1037-42.
[http://dx.doi.org/10.1002/gps.1013] [PMID: 14618556]
[39]
Haupt M, Kurz A, Jänner M. A 2-year follow-up of behavioural and psychological symptoms in Alzheimer’s disease. Dement Geriatr Cogn Disord 2000; 11(3): 147-52.
[http://dx.doi.org/10.1159/000017228] [PMID: 10765045]
[40]
Mega MS, Cummings JL, Fiorello T, Gornbein J. The spectrum of behavioral changes in Alzheimer’s disease. Neurology 1996; 46(1): 130-5.
[http://dx.doi.org/10.1212/WNL.46.1.130] [PMID: 8559361]
[41]
Mirakhur A, Craig D, Hart DJ, McLlroy SP, Passmore AP. Behavioural and psychological syndromes in Alzheimer’s disease. Int J Geriatr Psychiatry 2004; 19(11): 1035-9.
[http://dx.doi.org/10.1002/gps.1203] [PMID: 15481075]
[42]
Steffens DC, Maytan M, Helms MJ, Plassman BL. Prevalence and clinical correlates of neuropsychiatric symptoms in dementia. Am J Alzheimers Dis Other Demen 2005; 20(6): 367-73.
[http://dx.doi.org/10.1177/153331750502000611] [PMID: 16396442]
[43]
Devanand DP, Pradhaban G, Liu X, et al. Hippocampal and entorhinal atrophy in mild cognitive impairment: Prediction of Alzheimer disease. Neurology 2007; 68(11): 828-36.
[http://dx.doi.org/10.1212/01.wnl.0000256697.20968.d7] [PMID: 17353470]
[44]
Jack CR Jr, Knopman DS, Jagust WJ, et al. Tracking pathophysiological processes in Alzheimer’s disease: An updated hypothetical model of dynamic biomarkers. Lancet Neurol 2013; 12(2): 207-16.
[http://dx.doi.org/10.1016/S1474-4422(12)70291-0] [PMID: 23332364]
[45]
Pink A, Przybelski SA, Krell-Roesch J, et al. Cortical thickness and anxiety symptoms among cognitively normal elderly persons: The mayo clinic study of aging. J Neuropsychiatry Clin Neurosci 2017; 29(1): 60-6.
[http://dx.doi.org/10.1176/appi.neuropsych.15100378] [PMID: 27578447]
[46]
Bonthius DJ, Solodkin A, Van Hoesen GW. Pathology of the insular cortex in Alzheimer disease depends on cortical architecture. J Neuropathol Exp Neurol 2005; 64(10): 910-22.
[http://dx.doi.org/10.1097/01.jnen.0000182983.87106.d1] [PMID: 16215463]
[47]
Sun Y, Wang X, Wang Y, et al. Anxiety correlates with cortical surface area in subjective cognitive decline: APOE ε4 carriers versus APOE ε4 non-carriers. Alzheimers Res Ther 2019; 11(1): 50.
[http://dx.doi.org/10.1186/s13195-019-0505-0] [PMID: 31159873]
[48]
Mah L, Binns MA, Steffens DC. Anxiety symptoms in amnestic mild cognitive impairment are associated with medial temporal atrophy and predict conversion to Alzheimer disease. Am J Geriatr Psychiatry 2015; 23(5): 466-76.
[http://dx.doi.org/10.1016/j.jagp.2014.10.005] [PMID: 25500120]
[49]
Staekenborg SS, Gillissen F, Romkes R, et al. Behavioural and psychological symptoms are not related to white matter hyperintensities and medial temporal lobe atrophy in Alzheimer’s disease. Int J Geriatr Psychiatry 2008; 23(4): 387-92.
[http://dx.doi.org/10.1002/gps.1891] [PMID: 17907266]
[50]
Berlow YA, Wells WM, Ellison JM, Sung YH, Renshaw PF, Harper DG. Neuropsychiatric correlates of white matter hyperintensities in Alzheimer’s disease. Int J Geriatr Psychiatry 2010; 25(8): 780-8.
[http://dx.doi.org/10.1002/gps.2418] [PMID: 19946864]
[51]
García-Alberca JM, Florido M, Cáceres M, Sánchez-Toro A, Lara JP, García-Casares N. Medial temporal lobe atrophy is independently associated with behavioural and psychological symptoms in Alzheimer’s disease. Psychogeriatrics 2019; 19(1): 46-54.
[http://dx.doi.org/10.1111/psyg.12363] [PMID: 30084177]
[52]
García-Alberca JM, Mendoza S, Gris E, Royo JL, Cruz-Gamero JM, García-Casares N. White matter lesions and temporal atrophy are associated with cognitive and neuropsychiatric symptoms in patients with hypertension and Alzheimer’s disease. Int J Geriatr Psychiatry 2020; 35(11): 1292-300.
[http://dx.doi.org/10.1002/gps.5366] [PMID: 32584440]
[53]
Horínek D, Petrovický P, Hort J, et al. Amygdalar volume and psychiatric symptoms in Alzheimer’s disease: An MRI analysis. Acta Neurol Scand 2006; 113(1): 40-5.
[http://dx.doi.org/10.1111/j.1600-0404.2006.00540.x] [PMID: 16367898]
[54]
Poulin SP, Dautoff R, Morris JC, Barrett LF, Dickerson BC. Amygdala atrophy is prominent in early Alzheimer’s disease and relates to symptom severity. Psychiatry Res 2011; 194(1): 7-13.
[http://dx.doi.org/10.1016/j.pscychresns.2011.06.014] [PMID: 21920712]
[55]
Tovote P, Fadok JP, Lüthi A. Neuronal circuits for fear and anxiety. Nat Rev Neurosci 2015; 16(6): 317-31.
[http://dx.doi.org/10.1038/nrn3945] [PMID: 25991441]
[56]
Mosconi L, Tsui WH, Herholz K, et al. Multicenter standardized 18F-FDG PET diagnosis of mild cognitive impairment, Alzheimer’s disease, and other dementias. J Nucl Med 2008; 49(3): 390-8.
[http://dx.doi.org/10.2967/jnumed.107.045385] [PMID: 18287270]
[57]
Krell-Roesch J, Ruider H, Lowe VJ, et al. FDG-PET and neuropsychiatric symptoms among cognitively normal elderly persons: The mayo clinic study of aging. J Alzheimers Dis 2016; 53(4): 1609-16.
[http://dx.doi.org/10.3233/JAD-160326] [PMID: 27447426]
[58]
Krell-Roesch J, Syrjanen JA, Vassilaki M, et al. Brain regional glucose metabolism, neuropsychiatric symptoms, and the risk of incident mild cognitive impairment: The Mayo clinic study of aging. Am J Geriatr Psychiatry 2021; 29(2): 179-91.
[PMID: 32646634]
[59]
Hashimoto H, Monserratt L, Nguyen P, et al. Anxiety and regional cortical glucose metabolism in patients with Alzheimer’s disease. J Neuropsychiatry Clin Neurosci 2006; 18(4): 521-8.
[http://dx.doi.org/10.1176/jnp.2006.18.4.521] [PMID: 17135378]
[60]
Sultzer DL, Mahler ME, Mandelkern MA, et al. The relationship between psychiatric symptoms and regional cortical metabolism in Alzheimer’s disease. J Neuropsychiatry Clin Neurosci 1995; 7(4): 476-84.
[http://dx.doi.org/10.1176/jnp.7.4.476] [PMID: 8555751]
[61]
Pietrzak RH, Lim YY, Neumeister A, et al. Amyloid-β, anxiety, and cognitive decline in preclinical Alzheimer disease: A multicenter, prospective cohort study. JAMA Psychiatry 2015; 72(3): 284-91.
[http://dx.doi.org/10.1001/jamapsychiatry.2014.2476] [PMID: 25629787]
[62]
Hanseeuw BJ, Jonas V, Jackson J, et al. Association of anxiety with subcortical amyloidosis in cognitively normal older adults. Mol Psychiatry 2020; 25(10): 2599-607.
[http://dx.doi.org/10.1038/s41380-018-0214-2] [PMID: 30116029]
[63]
Krell-Roesch J, Lowe VJ, Neureiter J, et al. Depressive and anxiety symptoms and cortical amyloid deposition among cognitively normal elderly persons: The Mayo Clinic Study of Aging. Int Psychogeriatr 2018; 30(2): 245-51.
[http://dx.doi.org/10.1017/S1041610217002368] [PMID: 29198244]
[64]
Bensamoun D, Guignard R, Furst AJ, et al. Associations between neuropsychiatric symptoms and cerebral amyloid deposition in cognitively impaired elderly people. J Alzheimers Dis 2016; 49(2): 387-98.
[http://dx.doi.org/10.3233/JAD-150181] [PMID: 26484900]
[65]
Babulal GM, Ghoshal N, Head D, et al. Mood changes in cognitively normal older adults are linked to alzheimer disease biomarker levels. Am J Geriatr Psychiatry 2016; 24(11): 1095-104.
[http://dx.doi.org/10.1016/j.jagp.2016.04.004] [PMID: 27426238]
[66]
Lavretsky H, Siddarth P, Kepe V, et al. Depression and anxiety symptoms are associated with cerebral FDDNP-PET binding in middle-aged and older nondemented adults. Am J Geriatr Psychiatry 2009; 17(6): 493-502.
[http://dx.doi.org/10.1097/JGP.0b013e3181953b82] [PMID: 19472439]
[67]
Krell-Roesch J, Vassilaki M, Mielke MM, et al. Cortical β-amyloid burden, neuropsychiatric symptoms, and cognitive status: The Mayo Clinic Study of Aging. Transl Psychiatry 2019; 9(1): 123.
[http://dx.doi.org/10.1038/s41398-019-0456-z] [PMID: 30923322]
[68]
Johansson M, Stomrud E, Lindberg O, et al. Apathy and anxiety are early markers of Alzheimer’s disease. Neurobiol Aging 2020; 85: 74-82.
[http://dx.doi.org/10.1016/j.neurobiolaging.2019.10.008] [PMID: 31735378]
[69]
Ramakers IH, Verhey FR, Scheltens P, et al. Anxiety is related to Alzheimer cerebrospinal fluid markers in subjects with mild cognitive impairment. Psychol Med 2013; 43(5): 911-20.
[http://dx.doi.org/10.1017/S0033291712001870] [PMID: 22954311]
[70]
Goukasian N, Hwang KS, Romero T, et al. Association of brain amyloidosis with the incidence and frequency of neuropsychiatric symptoms in ADNI: A multisite observational cohort study. BMJ Open 2019; 9(12)e031947
[http://dx.doi.org/10.1136/bmjopen-2019-031947] [PMID: 31857304]
[71]
Nelson PT, Alafuzoff I, Bigio EH, et al. Correlation of Alzheimer disease neuropathologic changes with cognitive status: A review of the literature. J Neuropathol Exp Neurol 2012; 71(5): 362-81.
[http://dx.doi.org/10.1097/NEN.0b013e31825018f7] [PMID: 22487856]
[72]
Förstl H, Burns A, Luthert P, Cairns N, Lantos P, Levy R. Clinical and neuropathological correlates of depression in Alzheimer’s disease. Psychol Med 1992; 22(4): 877-84.
[http://dx.doi.org/10.1017/S0033291700038459] [PMID: 1488485]
[73]
Guadagna S, Esiri MM, Williams RJ, Francis PT. Tau phosphorylation in human brain: Relationship to behavioral disturbance in dementia. Neurobiol Aging 2012; 33(12): 2798-806.
[http://dx.doi.org/10.1016/j.neurobiolaging.2012.01.015] [PMID: 22382406]
[74]
Marshall GA, Fairbanks LA, Tekin S, Vinters HV, Cummings JL. Neuropathologic correlates of apathy in Alzheimer’s disease. Dement Geriatr Cogn Disord 2006; 21(3): 144-7.
[http://dx.doi.org/10.1159/000090674] [PMID: 16391476]
[75]
Rapp MA, Schnaider-Beeri M, Grossman HT, et al. Increased hippocampal plaques and tangles in patients with Alzheimer disease with a lifetime history of major depression. Arch Gen Psychiatry 2006; 63(2): 161-7.
[http://dx.doi.org/10.1001/archpsyc.63.2.161] [PMID: 16461859]
[76]
Tekin S, Mega MS, Masterman DM, et al. Orbitofrontal and anterior cingulate cortex neurofibrillary tangle burden is associated with agitation in Alzheimer disease. Ann Neurol 2001; 49(3): 355-61.
[http://dx.doi.org/10.1002/ana.72] [PMID: 11261510]
[77]
Wilson RS, Nag S, Boyle PA, et al. Brainstem aminergic nuclei and late-life depressive symptoms. JAMA Psychiatry 2013; 70(12): 1320-8.
[http://dx.doi.org/10.1001/jamapsychiatry.2013.2224] [PMID: 24132763]
[78]
Ehrenberg AJ, Suemoto CK, França Resende EP, et al. Neuropathologic correlates of psychiatric symptoms in Alzheimer’s disease. J Alzheimers Dis 2018; 66(1): 115-26.
[http://dx.doi.org/10.3233/JAD-180688] [PMID: 30223398]
[79]
Braak H, Braak E. Neuropathological stageing of Alzheimer-related changes. Acta Neuropathol 1991; 82(4): 239-59.
[http://dx.doi.org/10.1007/BF00308809] [PMID: 1759558]
[80]
Bennett DA, Schneider JA, Bienias JL, Evans DA, Wilson RS. Mild cognitive impairment is related to Alzheimer disease pathology and cerebral infarctions. Neurology 2005; 64(5): 834-41.
[http://dx.doi.org/10.1212/01.WNL.0000152982.47274.9E] [PMID: 15753419]
[81]
Ballard C, Neill D, O’Brien J, McKeith IG, Ince P, Perry R. Anxiety, depression and psychosis in vascular dementia: Prevalence and associations. J Affect Disord 2000; 59(2): 97-106.
[http://dx.doi.org/10.1016/S0165-0327(99)00057-9] [PMID: 10837878]
[82]
Segers K, Benoit F, Meyts JM, Surquin M. Anxiety symptoms are quantitatively and qualitatively different in dementia with Lewy bodies than in Alzheimer’s disease in the years preceding clinical diagnosis. Psychogeriatrics 2020; 20(3): 242-6.
[http://dx.doi.org/10.1111/psyg.12490] [PMID: 31782249]
[83]
Farrer LA, Cupples LA, Haines JL, et al. Effects of age, sex, and ethnicity on the association between apolipoprotein E genotype and Alzheimer disease. A meta-analysis. JAMA 1997; 278(16): 1349-56.
[http://dx.doi.org/10.1001/jama.1997.03550160069041] [PMID: 9343467]
[84]
Holmes SE, Esterlis I, Mazure CM, et al. β-amyloid, apoe and bdnf genotype, and depressive and anxiety symptoms in cognitively normal older women and men. Am J Geriatr Psychiatry 2016; 24(12): 1191-5.
[http://dx.doi.org/10.1016/j.jagp.2016.08.007] [PMID: 27742526]
[85]
Robertson J, Curley J, Kaye J, Quinn J, Pfankuch T, Raber J. apoE isoforms and measures of anxiety in probable AD patients and Apoe-/- mice. Neurobiol Aging 2005; 26(5): 637-43.
[http://dx.doi.org/10.1016/j.neurobiolaging.2004.06.003] [PMID: 15708438]
[86]
Michels A, Multhammer M, Zintl M, Mendoza MC, Klünemann HH. Association of apolipoprotein E ε4 (ApoE ε4) homozygosity with psychiatric behavioral symptoms. J Alzheimers Dis 2012; 28(1): 25-32.
[http://dx.doi.org/10.3233/JAD-2011-110554] [PMID: 22246233]
[87]
Mosca A, Sperduti S, Pop V, et al. Influence of apoe and rnf219 on behavioral and cognitive features of female patients affected by mild cognitive impairment or alzheimer’s disease. Front Aging Neurosci 2018; 10: 92.
[http://dx.doi.org/10.3389/fnagi.2018.00092] [PMID: 29755337]
[88]
Senanarong V, An SSA, Vo Van G, Limwongse C, Bagyinszky E, Kim S. Pathogenic psen1 glu184gly mutation in a family from thailand with probable autosomal dominant early onset alzheimer’s disease. Diagnostics (Basel) 2020; 10(3)E135
[http://dx.doi.org/10.3390/diagnostics10030135] [PMID: 32121568]
[89]
Sinning M, van Rooyen JP, Venegas-Francke P, Vásquez C, Behrens MI, Ramírez A. Clinical and genetic analysis of a chilean family with early-onset autosomal dominant Alzheimer’s disease. J Alzheimers Dis 2010; 21(3): 757-61.
[http://dx.doi.org/10.3233/JAD-2010-100135] [PMID: 20571222]
[90]
Swearer JM, O’Donnell BF, Parker M, Kane KJ, Drachman DA. Psychological features in persons at risk for familial Alzheimer’s disease. Am J Alzheimers Dis Other Demen 2001; 16(3): 157-62.
[http://dx.doi.org/10.1177/153331750101600311] [PMID: 11398564]
[91]
Ringman JM, Liang LJ, Zhou Y, et al. Early behavioural changes in familial alzheimer’s disease in the dominantly inherited alzheimer network. Brain 2015; 138(Pt 4): 1036-45.
[http://dx.doi.org/10.1093/brain/awv004] [PMID: 25688083]
[92]
Donovan NJ, Amariglio RE, Zoller AS, et al. Subjective cognitive concerns and neuropsychiatric predictors of progression to the early clinical stages of Alzheimer disease. Am J Geriatr Psychiatry 2014; 22(12): 1642-51.
[http://dx.doi.org/10.1016/j.jagp.2014.02.007] [PMID: 24698445]
[93]
Sinoff G, Werner P. Anxiety disorder and accompanying subjective memory loss in the elderly as a predictor of future cognitive decline. Int J Geriatr Psychiatry 2003; 18(10): 951-9.
[http://dx.doi.org/10.1002/gps.1004] [PMID: 14533128]
[94]
Snitz BE, Wang T, Cloonan YK, et al. Risk of progression from subjective cognitive decline to mild cognitive impairment: The role of study setting. Alzheimers Dement 2018; 14(6): 734-42.
[http://dx.doi.org/10.1016/j.jalz.2017.12.003] [PMID: 29352855]
[95]
Liew TM. Subjective cognitive decline, anxiety symptoms, and the risk of mild cognitive impairment and dementia. Alzheimers Res Ther 2020; 12(1): 107.
[http://dx.doi.org/10.1186/s13195-020-00673-8] [PMID: 32917264]
[96]
Palmer K, Berger AK, Monastero R, Winblad B, Bäckman L, Fratiglioni L. Predictors of progression from mild cognitive impairment to Alzheimer disease. Neurology 2007; 68(19): 1596-602.
[http://dx.doi.org/10.1212/01.wnl.0000260968.92345.3f] [PMID: 17485646]
[97]
Wadsworth LP, Lorius N, Donovan NJ, et al. Neuropsychiatric symptoms and global functional impairment along the Alzheimer’s continuum. Dement Geriatr Cogn Disord 2012; 34(2): 96-111.
[http://dx.doi.org/10.1159/000342119] [PMID: 22922821]
[98]
Rosenberg PB, Mielke MM, Appleby BS, Oh ES, Geda YE, Lyketsos CG. The association of neuropsychiatric symptoms in MCI with incident dementia and Alzheimer disease. Am J Geriatr Psychiatry 2013; 21(7): 685-95.
[http://dx.doi.org/10.1016/j.jagp.2013.01.006] [PMID: 23567400]
[99]
Somme J, Fernández-Martínez M, Molano A, Zarranz JJ. Neuropsychiatric symptoms in amnestic mild cognitive impairment: Increased risk and faster progression to dementia. Curr Alzheimer Res 2013; 10(1): 86-94.
[PMID: 23016837]
[100]
Ramakers IH, Visser PJ, Aalten P, Kester A, Jolles J, Verhey FR. Affective symptoms as predictors of Alzheimer’s disease in subjects with mild cognitive impairment: A 10-year follow-up study. Psychol Med 2010; 40(7): 1193-201.
[http://dx.doi.org/10.1017/S0033291709991577] [PMID: 19903364]
[101]
Devier DJ, Pelton GH, Tabert MH, et al. The impact of anxiety on conversion from mild cognitive impairment to Alzheimer’s disease. Int J Geriatr Psychiatry 2009; 24(12): 1335-42.
[http://dx.doi.org/10.1002/gps.2263] [PMID: 19319929]
[102]
Liu HC, Wang PN, Wang HC, et al. Conversion to dementia from questionable dementia in an ethnic Chinese population. J Geriatr Psychiatry Neurol 2007; 20(2): 76-83.
[http://dx.doi.org/10.1177/0891988706298626] [PMID: 17548776]
[103]
Bah TM, Goodman J, Iliff JJ. Sleep as a therapeutic target in the aging brain. Neurotherapeutics 2019; 16(3): 554-68.
[http://dx.doi.org/10.1007/s13311-019-00769-6] [PMID: 31376067]
[104]
Cox RC, Olatunji BO. A systematic review of sleep disturbance in anxiety and related disorders. J Anxiety Disord 2016; 37: 104-29.
[http://dx.doi.org/10.1016/j.janxdis.2015.12.001] [PMID: 26745517]
[105]
Kinney JW, Bemiller SM, Murtishaw AS, Leisgang AM, Salazar AM, Lamb BT. Inflammation as a central mechanism in Alzheimer’s disease. Alzheimers Dement (N Y) 2018; 4: 575-90.
[http://dx.doi.org/10.1016/j.trci.2018.06.014] [PMID: 30406177]
[106]
Furtado M, Katzman MA. Neuroinflammatory pathways in anxiety, posttraumatic stress, and obsessive compulsive disorders. Psychiatry Res 2015; 229(1-2): 37-48.
[http://dx.doi.org/10.1016/j.psychres.2015.05.036] [PMID: 26296951]
[107]
Arborelius L, Owens MJ, Plotsky PM, Nemeroff CB. The role of corticotropin-releasing factor in depression and anxiety disorders. J Endocrinol 1999; 160(1): 1-12.
[http://dx.doi.org/10.1677/joe.0.1600001] [PMID: 9854171]
[108]
Ouanes S, Popp J. High cortisol and the risk of dementia and alzheimer’s disease: A review of the literature. Front Aging Neurosci 2019; 11: 43.
[http://dx.doi.org/10.3389/fnagi.2019.00043] [PMID: 30881301]
[109]
Wuwongse S, Chang RC, Law AC. The putative neurodegenerative links between depression and Alzheimer’s disease. Prog Neurobiol 2010; 91(4): 362-75.
[http://dx.doi.org/10.1016/j.pneurobio.2010.04.005] [PMID: 20441786]
[110]
Leonpacher AK, Peters ME, Drye LT, et al. Effects of citalopram on neuropsychiatric symptoms in alzheimer’s dementia: Evidence from the citad study. Am J Psychiatry 2016; 173(5): 473-80.
[http://dx.doi.org/10.1176/appi.ajp.2016.15020248] [PMID: 27032628]
[111]
Nyth AL, Gottfries CG. The clinical efficacy of citalopram in treatment of emotional disturbances in dementia disorders. A Nordic multicentre study. Br J Psychiatry 1990; 157: 894-901.
[http://dx.doi.org/10.1192/bjp.157.6.894] [PMID: 1705151]
[112]
Raji MA, Brady SR. Mirtazapine for treatment of depression and comorbidities in Alzheimer disease. Ann Pharmacother 2001; 35(9): 1024-7.
[http://dx.doi.org/10.1345/aph.10371] [PMID: 11573849]
[113]
Lebert F, Pasquier F, Petit H. Behavioral effects of trazodone in Alzheimer’s disease. J Clin Psychiatry 1994; 55(12): 536-8.
[PMID: 7814348]
[114]
Gauthier S, Feldman H, Hecker J, et al. Efficacy of donepezil on behavioral symptoms in patients with moderate to severe Alzheimer’s disease. Int Psychogeriatr 2002; 14(4): 389-404.
[http://dx.doi.org/10.1017/S104161020200858X] [PMID: 12670060]
[115]
Savaskan E, Schnitzler C, Schröder C, Cajochen C, Müller-Spahn F, Wirz-Justice A. Treatment of behavioural, cognitive and circadian rest-activity cycle disturbances in Alzheimer’s disease: Haloperidol vs. quetiapine. Int J Neuropsychopharmacol 2006; 9(5): 507-16.
[http://dx.doi.org/10.1017/S1461145705006036] [PMID: 16316485]
[116]
Streim JE, Porsteinsson AP, Breder CD, et al. A randomized, double-blind, placebo-controlled study of aripiprazole for the treatment of psychosis in nursing home patients with Alzheimer disease. Am J Geriatr Psychiatry 2008; 16(7): 537-50.
[http://dx.doi.org/10.1097/JGP.0b013e318165db77] [PMID: 18591574]
[117]
Burke SL, O’Driscoll J, Alcide A, Li T. Moderating risk of Alzheimer’s disease through the use of anxiolytic agents. Int J Geriatr Psychiatry 2017; 32(12): 1312-21.
[http://dx.doi.org/10.1002/gps.4614] [PMID: 27805724]

Rights & Permissions Print Export Cite as
© 2022 Bentham Science Publishers | Privacy Policy